MedTrace Logo

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2010-07-23

No results posted yet for this study

Summary

Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes that are turned on, and turned off, by skin cells. Some of the drug induced changes in skin cells should also be visible using a special microscope. This study examines both types of changes.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Aldara (imiquimod 5% cream)

Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream

DRUG

Vehicle cream

Vehicle cream in 250 mg

Sponsors & Collaborators

  • Graceway Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • TC Meng, MD · Graceway Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2003-07-31
Completion
2003-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00335179 on ClinicalTrials.gov